High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy
- 1 April 2004
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 2 (4) , 309-313
- https://doi.org/10.1016/s1542-3565(04)00060-6
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- TNF-α, IL1-β, and immunoglobulin (GM and KM) gene polymorphisms in sarcoidosisHuman Immunology, 2002
- Changes in the Transmission of Tuberculosis in New York City from 1990 to 1999New England Journal of Medicine, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosisThorax, 2001
- Immunological Basis for Reactivation of Tuberculosis in MiceInfection and Immunity, 2001
- Invasive Pulmonary Aspergillosis Associated with Infliximab TherapyNew England Journal of Medicine, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Tuberculosis infection and anergy in hemodialysis patientsAmerican Journal of Kidney Diseases, 1998
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995